Viral inhibition

Patent metadata

Field	Value
Publication number	US-11364256-B2
Application number	US-202117201621-A
Country	US
Kind code	B2
Filing date	Mar 15, 2021
Priority date	Mar 13, 2020
Publication date	Jun 21, 2022
Grant date	Jun 21, 2022

Abstract

The technology relates to the use of at least one macrocyclic lactone such as ivermectin or moxidectin to inhibit a coronavirus in a subject in order to treat, prevent or reduce the risk of infection by the coronavirus.

First claim

What is claimed is:

1. A method of treating a coronavirus infection in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of at least one macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof, wherein the at least one macrocyclic lactone is ivermectin, moxidectin, or both ivermectin and moxidectin.

2. The method of claim 1 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 50%.

3. The method of claim 1 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 70%.

4. The method of claim 2 , wherein the method reduces the level of detectable coronavirus in the human subject over a period of 1 to 3 days after administration of the macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof.

5. The method of claim 1 , wherein the coronavirus is coronavirus 229E, coronavirus NL63, coronavirus OC43, SARS-CoV, MERS-CoV, SARS-CoV-2, or a variant thereof.

6. The method of claim 1 , wherein the coronavirus is SARS-CoV-2 or a SARS-CoV-2 variant.

7. The method of claim 1 , wherein the at least one macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof is administered to the human subject at a dose of about 0.1 mg/kg to about 1.0 mg/kg.

8. The method of claim 1 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 80%.

9. The method of claim 1 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 90%.

10. The method of claim 2 , wherein the method reduces the level of detectable coronavirus in the human subject over a period of 3 or more days after administration of the macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof.

11. A method of inhibiting a coronavirus in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of at least one macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof, wherein the at least one macrocyclic lactone is ivermectin, moxidectin, or both ivermectin and moxidectin.

12. The method of claim 11 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 50%.

13. The method of claim 11 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 70%.

14. The method of claim 12 , wherein the method reduces the level of detectable coronavirus in the human subject over a period of 1 to 3 days after administration of the macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof.

15. The method of claim 11 , wherein the coronavirus is coronavirus 229E, coronavirus NL63, coronavirus OC43, SARS-CoV, MERS-CoV, SARS-CoV-2, or a variant thereof.

16. The method of claim 11 , wherein the coronavirus is SARS-CoV-2 or a SARS-CoV-2 variant.

17. The method of claim 11 , wherein the at least one macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof is administered to the human subject at a dose of about 0.1 mg/kg to about 1.0 mg/kg.

18. The method of claim 11 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 80%.

19. The method of claim 11 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 90%.

20. The method of claim 12 , wherein the method reduces the level of detectable coronavirus in the human subject over a period of 3 or more days after administration of the macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof.

21. A method of preventing antibody-dependent enhanced (ADE) coronavirus infection in a human subject, comprising administering to the human subject a therapeutically effective amount of at least one macrocyclic lactone, or a salt, hydrate, solvate, tautomer, or stereoisomer thereof, wherein the at least one macrocyclic lactone is ivermectin, moxidectin, or both ivermectin and moxidectin.

22. The method of claim 21 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 50%.

23. The method of claim 21 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 70%.

24. The method of claim 22 , wherein the method reduces the level of detectable coronavirus in the human subject over a period of 1 to 3 days after administration of the macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof.

25. The method of claim 21 , wherein the coronavirus is coronavirus 229E, coronavirus NL63, coronavirus OC43, SARS-CoV, MERS-CoV, SARS-CoV-2, or a variant thereof.

26. The method of claim 21 , wherein the coronavirus is SARS-CoV-2 or a SARS-CoV-2 variant.

27. The method of claim 21 , wherein the at least one macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof is administered to the human subject at a dose of about 0.1 mg/kg to about 1.0 mg/kg.

28. The method of claim 21 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 80%.

29. The method of claim 21 , wherein the method reduces the level of detectable coronavirus in the human subject by at least 90%.

30. The method of claim 22 , wherein the method reduces the level of detectable coronavirus in the human subject over a period of 3 or more days after administration of the macrocyclic lactone or a salt, hydrate, solvate, tautomer, or stereoisomer thereof.

Assignees

• Univ Monash
• Melbourne Health

Inventors

• Wagstaff Kylie Michelle
• Caly Leon
• Jans David

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K31/365 Primary

  Lactones · CPC title

• A61K31/366

  having six-membered rings, e.g. delta-lactones · CPC title

• A61K31/7048 Primary

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61P31/14

  for RNA viruses · CPC title